


## Cidofovir

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 113852-37-2   |
| Formula:          | C <sub>8</sub> H <sub>14</sub> N <sub>3</sub> O <sub>6</sub> P  |
| Molecular Weight: | 279.19  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|               |   |
|---------------|---|
| Description   | Cidofovir ((S)-HPMPC) inhibits virus replication by specific inhibition of viral DNA synthesis.   |
| Targets(IC50) | Apoptosis,Endogenous Metabolite,DNA/RNA Synthesis,Virus Protease  |
| In vitro      | Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 µg/mL for Davis and 1.6 µg/mL for AD-169 strains,respectively. [1] Cidofovir also inhibits herpes simplex virus infection. In addition, Cidofovir blocks cell fusion induced by HSV-1 in monkey kidney cells and blocks the expression of HSV-l-specific proteins and the synthesis of viral DNA. [3]  |
| In vivo       | Cidofovir (5 mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. Cidofovir significantly reduces lymphocytosis and average tissue index of spleen in infected animals. [2]. Cidofovir suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of Cidofovir is that a single administration of the compound, even as late as 4 days after infection, confers significant protection against HSV-1 or HSV-2 infection. [4] Cidofovir inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice. [5] |
| Kinase Assay  | EGFR kinase assays: In vitro inhibitory enzyme kinetic assays using recombinant EGFR L858R/T790M and WT protein and are performed using the ATP/NADH coupled assay system in a 96-well format. WZ4002 is added to determine its inhibitory effects.   |

## Solubility Information

|            |   |
|------------|---|
| Solubility | H <sub>2</sub> O: 3.3 mg/mL (11.82 mM),Sonication is recommended.<br>DMSO: < 1 mg/mL (insoluble or slightly soluble)<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

### Preparing Stock Solutions

---

|       | <b>1mg</b> | <b>5mg</b> | <b>10mg</b> |
|-------|------------|------------|-------------|
| 1 mM  | 3.5818 mL  | 17.909 mL  | 35.8179 mL  |
| 5 mM  | 0.7164 mL  | 3.5818 mL  | 7.1636 mL   |
| 10 mM | 0.3582 mL  | 1.7909 mL  | 3.5818 mL   |
| 50 mM | 0.0716 mL  | 0.3582 mL  | 0.7164 mL   |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Snoeck R, et al. Antimicrob Agents Chemother, 1988, 32(12), 1839-1844.
- Li SB, et al. Antiviral Res, 1990, 13(5), 237-252.
- Chatterjee S, et al. Antiviral Res., 1992, 19(3), 181-192.
- De Clercq E, et al. Antimicrob Agents Chemother, 1991, 35(4), 701-706.
- Redondo P, et al. Br J Dermatol, 2000, 143(4), 741-748.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481